Surgical management of hereditary pheochromocytoma
- 30 April 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American College of Surgeons
- Vol. 198 (4), 525-534
- https://doi.org/10.1016/j.jamcollsurg.2003.12.001
Abstract
Background Surgical treatment of hereditary pheochromocytoma remains controversial because of the need for lifelong corticosteroid therapy and the risk of Addisonian crisis associated with bilateral total adrenalectomy. We examined our large series of patients with hereditary pheochromocytoma to evaluate postsurgical outcomes, particularly in those who underwent cortical-sparing adrenalectomy. Study design We retrospectively reviewed the outcomes of all patients with histopathologic diagnoses of hereditary pheochromocytoma treated at our institution from 1962 to 2003. Familial disease was initially determined by pedigree analysis, genetic testing, or both for multiple endocrine neoplasia (MEN) types 1, 2A, or 2B; von Hippel-Lindau disease (VHL); neurofibromatosis type 1 (NF-1); or familial paraganglioma syndrome (FP). Results Adrenal pheochromocytomas were present in 56 of 59 patients (95%): MEN2A (39), MEN2B (7), VHL (6), MEN1 (2), NF-1 (2). Paragangliomas (extraadrenal pheochromocytomas) were present in the remaining 3 of 59 patients (5%): FP (2) and NF-1 (1). Thirty-eight of 56 patients with pheochromocytomas had cumulative operations resulting in total or subtotal bilateral adrenalectomy. Acute adrenal insufficiency (Addisonian crisis) occurred in 4 of these 38 patients (11%). Cortical-sparing adrenalectomy was performed in 26 patients who underwent bilateral adrenal resection; 17 (65%) were corticosteroid independent at a median followup of 71 months. Recurrent pheochromocytoma developed in an adrenal remnant in 3 of 30 patients (10%) who underwent unilateral or bilateral cortical-sparing procedures. Metastatic disease did not develop in any patient with pheochromocytoma, but has occurred in two of three patients with paragangliomas. Conclusions Our data suggest that a cortical-sparing adrenalectomy can successfully avoid the need for corticosteroid replacement in the majority of patients who undergo a bilateral adrenalectomy. Long-term followup should include monitoring of the remnant gland for recurrent pheochromocytoma with yearly biochemical screening studies.Keywords
This publication has 25 references indexed in Scilit:
- Pheochromocytoma: The Expanding Genetic Differential DiagnosisJNCI Journal of the National Cancer Institute, 2003
- The pressure rises: update on the genetics of phaeochromocytoma.Human Molecular Genetics, 2002
- New Insights into the Genetics of Familial Chromaffin Cell TumorsAnnals of the New York Academy of Sciences, 2002
- New Therapeutic and Surgical Approaches for Sporadic and Hereditary PheochromocytomaAnnals of the New York Academy of Sciences, 2002
- Germ-Line Mutations in Nonsyndromic PheochromocytomaNew England Journal of Medicine, 2002
- Recent Advances in Genetics, Diagnosis, Localization, and Treatment of PheochromocytomaAnnals of Internal Medicine, 2001
- Pheochromocytoma: Inherited associations, bilaterality, and cortex preservationSurgery, 2000
- Complications after Bilateral Adrenalectomy for Phaeochromocytoma in Multiple Endocrine Neoplasia Type 2 - a Plea to Conserve Adrenal FunctionThe European Journal of Surgery, 1999
- Preserved Adrenocortical Function After Laparoscopic Bilateral Adrenal Sparing Surgery for Hereditary PheochromocytomaJournal of Clinical Endocrinology & Metabolism, 1999
- Management of Pheochromocytomas in Patients with Multiple Endocrine Neoplasia Type 2 SyndromesAnnals of Surgery, 1993